Role of Nitric Oxide in Motor Control: Implications for Parkinsons Disease Pathophysiology and Treatment

Author(s): Elaine Del-Bel, Fernando Eduardo Padovan-Neto, Rita Raisman-Vozari, Marcio Lazzarini

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 5 , 2011

Become EABM
Become Reviewer
Call for Editor


According to classical thinking about Parkinsons disease, loss of dopaminergic input from the substantia nigra pars compacta leads to overactivity and underactivity of the indirect and direct output pathways, respectively, in the basal ganglia. Administration of the dopamine precursor L-DOPA (l-3, 4-dihydroxyphenylalanine) is proposed to induce changes in the opposite directions. L-DOPA is the most used drug to treat Parkinsons disease symptoms. After repeated treatment with this compound, however, disabling secondary effects such as the abnormal involuntary movements usually appear. Nitric oxide is a free radical that can also acts as an atypical neurotransmitter and influences dopamine-mediated neurotransmission. In this paper we will briefly review the role of nitric oxide on motor control and in Parkinsons disease, particularly a possible role of nitric oxide in L-DOPA induced dyskinesia in rodents. Recent results show that nitric oxide synthase inhibition reduces L-DOPA-induced dyskinesia in rats and mice. The effect is dose-dependent, does not suffer tolerance nor interferes with L-DOPA positive motor effects. These preclinical findings suggest that nitric oxide is a promising therapeutic target for the reduction of L-DOPA-induced dyskinesia.

Keywords: 7-Nitroindazole, Motor behaviour, Nitric oxide synthase inhibitor, Dopamine, Mice, L-DOPA, Dyskinesia, Parkinson's disease, Abnormal involuntary movements

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [471 - 488]
Pages: 18
DOI: 10.2174/138161211795164176
Price: $65

Article Metrics

PDF: 31